How CAR T-Cell Therapy Works—Reprogramming Immunity
CAR T-cell therapy genetically engineers a patient's own immune cells to hunt and destroy cancer. Once limited to blood cancers, it is now expanding into autoimmune diseases and may soon be delivered with a single injection.
Turning the Immune System Into a Guided Missile
Chimeric antigen receptor T-cell therapy — better known as CAR T-cell therapy — is a form of immunotherapy that reprograms a patient's own immune cells to recognize and destroy cancer. Unlike chemotherapy, which attacks healthy and malignant cells alike, CAR T cells are precision weapons that lock onto specific proteins found on tumour surfaces.
First approved by the U.S. Food and Drug Administration in 2017, six CAR T-cell products are now cleared to treat various blood cancers, including certain lymphomas, leukaemias, and multiple myeloma. The approach has produced lasting remissions in patients who had exhausted every other option — and researchers are now pushing the technology far beyond oncology.
How the Process Works
Traditional CAR T-cell therapy is a multi-step procedure that takes several weeks:
- Collection (apheresis): A patient's blood is drawn through a machine that separates out T cells — the immune system's natural killer cells. The remaining blood is returned to the body.
- Engineering: In a specialized laboratory, scientists insert a synthetic gene into the T cells. This gene encodes the chimeric antigen receptor (CAR), a custom-built protein designed to recognize a target on cancer cells — most commonly CD19, a molecule found on the surface of B-cell cancers.
- Expansion: The modified cells are multiplied into hundreds of millions of copies over roughly two to four weeks.
- Infusion: Before the CAR T cells are returned, the patient typically undergoes a short course of lymphodepleting chemotherapy to make room for the new cells. The infusion itself takes as little as five to thirty minutes.
Once inside the body, the engineered cells patrol the bloodstream. When a CAR T cell encounters a cancer cell carrying the target protein, it binds to it and triggers a killing response — then multiplies further, creating an expanding army of cancer hunters.
Side Effects and Risks
CAR T-cell therapy can produce serious side effects. The most common is cytokine release syndrome (CRS), an inflammatory cascade triggered when the engineered cells activate en masse. Symptoms range from fever and chills to dangerous drops in blood pressure. A second concern is neurotoxicity, which can cause confusion, seizures, or difficulty speaking. According to the American Cancer Society, both conditions are almost always reversible with prompt medical intervention, but patients typically remain near a treatment centre for at least a month after infusion.
The Cost Problem
Because each treatment is individually manufactured for a single patient, CAR T-cell therapy remains extraordinarily expensive. The cells alone cost between $300,000 and $475,000, and total treatment expenses — including hospitalization, monitoring, and managing side effects — can exceed $500,000. The bespoke manufacturing process, which requires specialized facilities and weeks of production time, is the primary cost driver.
In Vivo CAR T: A Single-Injection Future
A new generation of research aims to eliminate the factory entirely. In vivo CAR T-cell therapy uses targeted delivery systems — lipid nanoparticles or engineered viral vectors — to reprogram T cells directly inside the patient's body. In preclinical studies at the Innovative Genomics Institute, a single injection of a two-particle system cleared all detectable cancer in nearly all mice within two weeks.
The approach has already reached human trials. Early results from the first-in-human study in multiple myeloma showed that the off-the-shelf injection generated CAR T cells in patients' blood without requiring lymphodepletion — a potential game-changer for accessibility and cost.
Beyond Cancer: Autoimmune Disease
Perhaps the most surprising frontier is autoimmune disease. Because conditions like lupus are driven by rogue B cells that attack healthy tissue, the same anti-CD19 CAR T cells designed for cancer can target them. In early clinical results reported by Penn Medicine and German researchers, all lupus patients treated achieved drug-free remission, with some remaining symptom-free for over a year. Trials are now expanding into scleroderma, myasthenia gravis, and other autoimmune conditions.
What Lies Ahead
CAR T-cell therapy has already transformed blood cancer treatment. The next decade will likely determine whether in vivo delivery can bring costs down to a fraction of current levels, and whether the technology can be extended to solid tumours — which account for roughly 90% of all cancers but present far more complex targeting challenges. If even some of these promises hold, CAR T cells could become one of the most important medical advances of the century.
